martes, 22 de septiembre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 24, 2026

Palantir Drops 5% as Tech Sells Off: Is PLTR Being Punished Unfairly?

View original at finance.yahoo.com

Palantir Drops 5% as Tech Sells Off: Is PLTR Being Punished Unfairly? Quick Read Palantir Technologies (PLTR) posted Q4 2025 revenue of $1.406B, up 70% year-over-year, with free cash flow of $791M, while guidance for 2026 revenue is $7.2B (61% growth) with U.S…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Palantir's Rule of 40 score is now an incredible 127%
60% confidence
Announcing a 2026 revenue growth guide of 61% year-over-year
60% confidence
Palantir is an n of 1 (unique in the market)
60% confidence
U.S. commercial revenue grew 137% year-over-year
60% confidence
U.S. revenue grew 93% year-over-year last quarter
60% confidence

Data points we hold from this source

NASDAQ · index change

-1 percent

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets

Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

Berkshire Hathaway

Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,983

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,983 hechos verificados con la fuente5,304 documentos fuente archivados

Consulta estos datos → isubstrate.com

Palantir Drops 5% as Tech Sells Off: Is PLTR Being Punished Unfairly? — Source | Via News | es.VIA.NEWS